ClinicalTrials.Veeva

Menu
H

Health Concepts | Rapid City, SD

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Dupilumab
Amlitelimab
PF-06700841
Olezarsen
JNJ-77242113
Relamorelin
PF-04965842
Hydrocodone Bitartrate
Upadacitinib
Tanezumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 110 total trials

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD) over up...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol i...

Enrolling
Gout
Drug: Allopurinol
Drug: Dotinurad

The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol i...

Enrolling
Tophaceous Gout
Drug: Allopurinol
Drug: Dotinurad

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib 30mg Dose
Drug: Upadacitinib 15mg Dose

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to sev...

Active, not recruiting
Plaque Psoriasis
Drug: Ustekinumab
Drug: Matching Placebo to Ustekinumab

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluat...

Active, not recruiting
Atopic Dermatitis
Drug: Placebo
Drug: Lutikizumab

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: Apremilast

This is a parallel, Phase 2 multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study to investigate the efficacy and saf...

Active, not recruiting
Alopecia Areata
Drug: Placebo
Drug: Amlitelimab

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Placebo
Drug: Upadacitinib

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Active, not recruiting
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

This is a parallel, Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of lun...

Active, not recruiting
Dermatitis Atopic
Drug: Lunsekimig
Drug: Placebo

The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. CO...

Enrolling
Moderate to Severe Chronic Obstructive Pulmonary Disease
Drug: Placebo
Drug: PF-07275315-dose 2

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and a...

Active, not recruiting
Moderate Plaque Psoriasis
Drug: Risankizumab
Drug: Deucravacitinib

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Olezarsen

This is an open-label, Phase 2/Phase 3, long-term extension study for treatment of participants of previous amlitelimab clinical trials in moderate t...

Invitation-only
Dermatitis Atopic
Drug: Topical calcineurin inhibitors
Drug: Topical corticosteroids

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: AR1001

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to...

Enrolling
Asthma
Drug: Placebo
Drug: Dupilumab

Trial sponsors

Pfizer logo
AbbVie logo
Sanofi logo
Janssen (J&J Innovative Medicine) logo
Allergan logo
Ionis Pharmaceuticals logo
Amgen logo
B
Boehringer Ingelheim logo
Bristol-Myers Squibb (BMS) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems